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The term “immunogenic cell death” (ICD) is commonly employed to indicate a peculiar
instance of regulated cell death (RCD) that engages the adaptive arm of the immune
system. The inoculation of cancer cells undergoing ICD into immunocompetent animals
elicits a specific immune response associated with the establishment of immunological
memory. Only a few agents are intrinsically endowed with the ability to trigger ICD.
These include a few chemotherapeutics that are routinely employed in the clinic, like
doxorubicin, mitoxantrone, oxaliplatin, and cyclophosphamide, as well as some agents
that have not yet been approved for use in humans. Accumulating clinical data indicate
that the activation of adaptive immune responses against dying cancer cells is associated
with improved disease outcome in patients affected by various neoplasms. Thus, novel
therapeutic regimens that trigger ICD are urgently awaited. Here, we discuss current
combinatorial approaches to convert otherwise non-immunogenic instances of RCD into
bona fide ICD.
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Introduction
The expression “immunogenic cell death” (ICD) generally refers to a functionally peculiar case of
regulated cell death (RCD) that – in immunocompetent hosts – is capable of activating an adaptive
immune response against dead cell-associated antigens (1–5). Of note, ICD generally (but not
obligatorily) manifests with apoptotic morphological features, and at least some of its manifestations
depend on components of the apoptotic apparatus (6–8). Irrespective of these morphological and
biochemical considerations, immunocompetent mice injected s.c. with cancer cells succumbing to
Abbreviations: APC, antigen-presenting cell; CALR, calreticulin; CTLA4, cytotoxic T lymphocyte-associated protein 4;
CXCL10, chemokine (C–X–C motif) ligand 10; DAMP, damage-associated molecular pattern; EIF2A, eukaryotic translation
initiation factor 2A, 65 kDa; ER, endoplasmic reticulum; HMGB1, high-mobility group box 1; ICD, immunogenic cell death;
IFN, interferon; IFNAR, interferon (alpha, beta, and omega) receptor; mAb, monoclonal antibody; P2RX7, purinergic receptor
P2X, ligand gated ion channel, 7; P2RY2, purinergic receptor P2Y, G-protein coupled, 2; RCD, regulated cell death; siRNA,
small-interfering RNA; TLR, toll-like receptor.
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bona fide ICD (in the absence of any adjuvant) develop a cellular
immune response associated with the establishment of immuno-
logical memory that protects them from a subsequent challenge
with living cells of the same type (1–3). Importantly, vaccination
experiments of this type, involving murine cells and syngeneic
mice, remain the gold-standardmethod to identify bona fide ICD,
though several tests have been developed to detect some of its
cellular manifestations (see below) (2, 3, 9, 10).
Only a few lethal stimuli are intrinsically endowed with the
ability to trigger ICD (9, 11–14). These include some chemother-
apeutic agents that are employed in the clinic, including (1) vari-
ous anthracyclines (i.e., doxorubicin, epirubicin, and idarubicin),
which are commonly used against a wide panel of malignant
conditions (15–17); (2) mitoxantrone, an anthracenedione gen-
erally used for the treatment of acute myeloid leukemia, breast
carcinoma, non-Hodgkin’s lymphoma, and prostate carcinoma
(15, 16); (3) oxaliplatin, a platinum derivative approved for use in
combination with 5-fluorouracil to treat advanced colorectal car-
cinoma (18, 19); (4) cyclophosphamide, an alkylating agent that is
employed against various neoplastic and autoimmune conditions
(20–23); and (5) bortezomib, a proteasomal inhibitor approved for
the therapy of multiple myeloma and mantle cell lymphoma (24–
26). Specific forms of irradiation as well as photodynamic therapy,
both of which are habitually employed for the treatment of various
neoplasms, have also been shown to trigger bona fide ICD (27–34).
Finally, a bunch of hitherto experimental agents is intrinsically
endowed with the capacity to initiate ICD, including (but not lim-
ited to) some oncolytic viruses (35–39), themicrotubular inhibitor
patupilone (40–42), and elevated hydrostatic pressures (43).
According to accepted models, ICD relies on the establishment
of adaptive stress responses that promote the spatiotemporally
coordinated emission of endogenous danger signals from dying
cells (44, 45). The endogenous molecules that dispatch danger
signals in response to stress are cumulatively known as “damage-
associated molecular patterns” (DAMPs) and operate upon bind-
ing to receptors expressed by bystander cells, including cellular
components of both the innate and adaptive immune system (2,
46–49). As it stands, four DAMPs have been shown to be required
for RCD as induced by anthracyclines to be perceived as immuno-
genic, namely, (1) the exposure of the endoplasmic reticulum
(ER) chaperone calreticulin (CALR) on the outer surface of the
plasma membrane (16); (2) the secretion of ATP (50); (3) the
production of type I interferon (IFN) (51); and (4) the release of
the non-histone chromatin-binding protein high-mobility group
box 1 (HMGB1) into the extracellular space (52). This said, it
cannot be formally excluded that other hitherto undiscovered
DAMPs are required for anthracycline-elicited RCD to promote
an adaptive immune response. Along similar lines, not all these
DAMPsmay be required for RCD as induced by agents other than
anthracyclines to be perceived as immunogenic (53–55).
In this context, i.e., anthracycline-induced ICD, CALR expo-
sure obligatorily relies on the establishment of a pre-mortem ER
stress response centered around the phosphorylation of eukary-
otic translation initiation factor 2A, 65 kDa (EIF2A) (7, 56), ATP
secretion requires the induction of autophagy (57), and type
I IFN production stems from toll-like receptor 3 (TLR3) sig-
naling (51). The molecular mechanisms underlying the ability
of anthracyclines and other ICD inducers to promote HMGB1
release remain obscure (2, 3). Cumulatively, these DAMPs recruit
antigen-presenting cells (APCs) to sites of active ICD and stim-
ulate the uptake, processing, and presentation of dead cell-
associated antigens, eventually resulting in the priming of an
adaptive immune response (2, 3). In particular, CALR promotes
antigen uptake by APCs by binding to low density lipoprotein
receptor-related protein 1 (LRP1, best known as CD91) (58);
ATP stimulates the recruitment of APCs and their activation
upon binding to purinergic receptor P2Y, G-protein coupled, 2
(P2RY2) and purinergic receptor P2X, ligand-gated ion channel,
7 (P2RX7), respectively (50, 59, 60); type I IFNs exert immunos-
timulatory effects via IFN (alpha, beta, and omega) receptors
(IFNARs) (51); andHMGB1 does so through TLR4 and advanced
glycosylation end product-specific receptor (AGER, best known
as RAGE) (52, 61).
A detailed discussion of themolecular and cellularmechanisms
involved in the detection of ICD-associated DAMPs goes beyond
the scope of this review and can be found in Ref. (2, 3). How-
ever, it is important to note that the failure of cancer cells to
emit one (or more) of these DAMPs completely compromises the
immunogenicity of RCD (2, 3). Thus, at odds with their wild-
type counterparts, Calr /  murine CT26 colorectal cells exposed
to anthracyclines are unable to vaccinate mice against a subse-
quent inoculation with malignant cells of the same type (16).
The same holds true in several other situations in which adaptive
responses cannot proceed normally, including the genetic inhi-
bition of autophagy (e.g., upon the expression of short-hairpin
RNAs targeting the essential autophagy proteins Atg5 or Atg7)
or the unfolded protein response (e.g., upon the expression of a
non-phosphorylatable variant of EIF2A) (7, 57, 62, 63).
Accumulating clinical evidence indicates that the
(re-)activation of a proficient immune response against malignant
cells is associated with improved disease outcome in patients
affected by a wide panel of neoplasms (64–68), in particular
when malignant lesions are highly infiltrated by immune effector
cells prior to therapy (69). Considerable efforts are therefore
being devoted to the development of clinically implementable
strategies that (re-)instate anticancer immunosurveillance (70,
71). So far, the most successful of these approaches involves
the administration of monoclonal antibodies (mAbs) that
block immunosuppressive receptors expressed by activated
T cells, such as cytotoxic T lymphocyte-associated protein 4
(CTLA4) and programed cell death 1 (PDCD1, best known as
PD-1) (72, 73). Three distinct checkpoint blockers of this type,
namely, the CTLA4-targeting mAb ipilimumab and the PD-1-
targeting mAbs nivolumab and pembrolizumab, are approved
by the US Food and Drug Administration and other regulatory
agencies worldwide for use as standalone immunotherapeutic
interventions in melanoma patients (74–77). In addition, the
administration of checkpoint blockers has been shown to
improve the clinical profile of various chemotherapeutic and
immunotherapeutic agents (78). Along similar lines, various
combinatorial immuno(chemo)therapeutic regimens are being
investigated in clinical trials for their ability to mediate superior
antineoplastic effects as compared to monotherapies based on
their constituents (79, 80). In this framework, various attempts are
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beingmade to render immunogenic otherwise non-immunogenic
instances of therapy-induced RCD, thereby converting them into
bona fide ICD (79, 81–84). This can be due to molecular defects
that prevent cancer cells from emitting DAMPs appropriately,
as mentioned above, as well as to the intrinsic features of the
therapeutic agent under consideration (Table 1). For instance,
at odds with its derivative oxaliplatin, cisplatin is intrinsically
unable to trigger ICD since it does not stimulate the exposure of
CALR on the outer surface of the plasma membrane (18, 19, 85).
Here, we discuss strategies to convert non-immunogenic
instances of RCD into bona fide ICD. In particular, we will review
approaches for (1) correcting the incapacity of some therapeutic
agents to kill cancer cells while provoking the emission of one
or more DAMP(s); or (2) complementing the missing DAMP(s)
with exogenous interventions. On the contrary, we will not dwell
on strategies that boost the immunogenicity of RCD by operating
downstream of DAMP-sensing receptors.
Combinatorial Strategies to Restore CALR
Exposure
Some anticancer therapeutics efficiently kill cancer cells (hence
promoting the release of HMGB1) and stimulate the secretion of
both ATP and type I IFNs, but selectively fail to promote CALR
exposure. Most often, such a defect originates from the inability
of these agents to trigger an ER stress response resulting in EIF2A
phosphorylation (56, 114), and hence can be corrected by the co-
administration of an ER stressors. As mentioned above, cisplatin
is one of the antineoplastic agents that fail to trigger bona fide
ICD as it does not drive a robust ER stress response (18, 19,
85). The ER-stressing agents that have been shown to correct this
defect, hence rendering cisplatin-induced RCD immunogenic,
include thapsigargin, an inhibitor of various members of the
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) (19, 114);
tunicamycin, an inhibitor of N-glycosylation (19, 94, 114); pyri-
doxine, a cell-permeant precursor of bioactive vitamin B6 (90, 91,
115); and ZnCl2 (92). Similar results have been obtained by estab-
lishing an ER stress response through the enforced overexpression
of reticulon 1 (RTN1), an ER protein involved in vesicular traf-
ficking and secretion (116, 117). The latter approach is obviously
incompatible with clinical applications. Nonetheless, these data
reinforce the notion that the immunogenicity of cisplatin-induced
RCD can be restored by various interventions that induce an ER
stress (94).
Another strategy that successfully restores CALR exposure in
cells succumbing to chemicals that per se do not enable this
phenomenon consists in the co-administration of inhibitors of
the EIF2A phosphatase composed of protein phosphatase 1, reg-
ulatory subunit 15A (PPP1R15A, best known as GADD34), and
pyrophosphatase (inorganic) 1 (PPA1, best known as PP1), result-
ing in accruedEIF2Aphosphorylation even in the absence of overt
ER stress (16). Thus, whereas CT26 cells treated with etoposide
(a topoisomerase II inhibitor currently approved for the treat-
ment of various malignancies) (118, 119) do not expose CALR
as they die, and hence fail to vaccinate mice against a subsequent
challenge with neoplastic cells of the same type, they efficiently
do so in the presence of tautomycin, calyculin A, and salubrinal
(three distinct GADD34/PP1 inhibitors) (16). Similar results have
been obtained with the small-interfering RNA (siRNA)-mediated
downregulation of PP1 orGADD34 (16), as well as with short cell-
permeant peptides that disrupt the physical interaction between
these two proteins (102). Although siRNA- and peptide-based
strategies may not be easily implemented in clinical settings, these
results corroborate the specificity of tautomycin, calyculin A, and
salubrinal, and lend further support to the notion that interven-
tions that stimulate EIF2A phosphorylation efficiently promote
CALR exposure even in the absence of overt ER stress (120).
At least theoretically, the co-administration of ER stressors or
molecules that promote EIF2A phosphorylation can be harnessed
to reconstitute the immunogenicity of RCD induced by all anti-
cancer agents that per se do not stimulate CALR exposure on the
cell surface but provoke ATP secretion, type I IFN production,
and HMGB1 release. In addition, the inability of some anticancer
agents to cause the translocation of CALR to the outer leaflet of
the plasma membrane can be corrected, at least in some settings,
by the co-administration of exogenous, recombinant CALR (7,
16, 106). CALR is indeed relatively “sticky” and its absorption on
malignant cells succumbing to non-immunogenic RCD in vitro
has been shown to fully restore the ability of these cells to vaccinate
syngeneic mice against a subsequent neoplastic challenge (16).
To the best of our knowledge, however, whether the systemic
or intratumoral administration of recombinant CALR to tumor-
bearing mice treated with non-immunogenic therapeutics is able
to convert them into bona fide ICD inducers has not been tested
yet. As compared to administration of small molecules that estab-
lish an ER stress response or promote EIF2A phosphorylation, the
use of recombinant CALR appears advantageous in that (at least
theoretically) it would complement the lack of CALR exposure
in all scenarios, irrespective of the underlying molecular defects
(including the downregulation or loss of CALR itself). However,
such an approachmay not be implementable in the clinic, owing to
pharmacodynamic and pharmacokinetic issues (e.g., distribution
of the recombinant protein, serum half-life, etc: : :) as well as eco-
nomic considerations. Current efforts are therefore being focused
on the identification of novel (and the refinement of existing)
smallmolecule-based strategies to stimulate CALR exposure upon
the establishment of an ER stress or the induction of EIF2A
phosphorylation.
Combinatorial Strategies to Boost ATP
Secretion
In some settings, anticancer agents kill malignant cells in an
efficient fashion (which corresponds to a consistent release of
HMGB1), while stimulating the exposure of CALR and the pro-
duction of type I IFN, but this is not accompanied by the accumu-
lation of extracellular ATP (57, 121), a defect that can stem from
at least three different causes. First, some therapeutic agents are
unable to stimulate (or even inhibit) autophagic responses, which
are required for dying cells to secrete ATP in sufficient amount
for signaling via P2RY2 and P2RX7 receptors (57). Second, some
malignant cells bear genetic or epigenetic defects that affect the
molecular machinery for autophagy (122, 123). These cells are
intrinsically unable to preserve the intracellular ATP pool in the
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TABLE 1 | Immunogenicity of chemotherapy-induced regulated cell death (examples).
Drug CALR
exposure
ATP
secretion
Type I IFN
production
HMGB1
release
aBona fide
ICD inducer
Restoration
of ICD
Reference
5-Fluorouracil Debated No n.d. Yes n.d. RT (16)
(86)
(87)
Bleomycin Yes Yes Yes Yes Yes n.a. (88)
Bortezomib Yes n.d. Yes Yes Yes n.a. (24)
(25)
(26)
(89)
Camptothecin Debated No n.d. Yes No n.d. (16)
(87)
Carboplatin Partial Yes n.d. Partial No RT (16)
(86)
Cisplatin No Yes n.d. Yes No Pyridoxine (19)
Thapsigargin (90)
Tunicamycin (91)
ZnCl2 (92)
(93)
(94)
Cyclophosphamide Yes Yes Yes Yes Yes n.a. (20)
(21)
(95)
Digitoxin Yes Yes n.d. Partial No Cytotoxic agents (81)
Digoxin (83)
Docetaxel Yes No n.d. No No n.d. (96)
(97)
Doxorubicin Yes Yes Yes Yes Yes n.a. (15)
(16)
(17)
(51)
(98)
(99)
Epirubicin Yes Yes n.d. Yes Yes n.a. (16)
(17)
Etoposide No Yes n.d. Yes No Calyculin A (16)
Salubrinal (17)
Tautomycin (93)
PP1/GADD34-targeting peptides (100)
2-deoxyglucose (101)
(102)
Gemcitabine No Partial n.d. Yes No PX-478 (103)
Idarubicin Yes n.d. n.d. Yes Yes n.a. (17)
(16)
(104)
Irinotecan n.d. n.d. n.d. Yes n.d. n.d. (105)
Mafosfamide Yes n.d. n.d. Yes Yes n.d. (20)
(Continued)
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TABLE 1 | Continued
Drug CALR
exposure
ATP
secretion
Type I IFN
production
HMGB1
release
aBona fide
ICD inducer
Restoration
of ICD
Reference
Melphalan Debated n.d. n.d. Yes n.d. n.d. (106)
(107)
(108)
Mitomycin C Debated No n.d. Yes No n.d. (16)
(87)
Mitoxantrone Yes Yes Yes Yes Yes n.a. (7)
(16)
(17)
(51)
(57)
(93)
(109)
Oxaliplatin Yes Yes Yes n.d. Yes n.a. (7)
(18)
(52)
(57)
(93)
(110)
Patupilone Yesb n.d. Yes Yesb Yesb n.a. (41)
(42)
Temozolomide No Yes n.d. Yes n.d. Oncolytic virotherapy (111)
Cyclophosphamide (112)
Vemurafenib Yes n.d. n.d. Yes n.d. n.d. (103)
(113)
CALR, calreticulin; HMGB1, high-mobility group box 1; ICD, immunogenic cell death; IFN, interferon; n.a., not applicable; n.d., not determined; RT, radiation therapy.
aAs determined in gold-standard vaccination experiments.
bUnpublished observations from our group.
course of stress responses, resulting in limited ATP secretion
during death (124). Third, some neoplastic cells express high
levels of either ectonucleoside triphosphate diphosphohydrolase 1
(ENTPD1, best known as CD39) or 50-nucleotidase, ecto (NT5E,
best known as CD73), two membrane-bound nucleotidases that
degrade extracellular ATP (125).
So far, one general strategy has been shown to restore extra-
cellular ATP concentrations to levels that are compatible with
the efficient recruitment and activation of APCs, namely, the
pharmacological inhibition of CD39. Thus, CT26 cells lack-
ing essential components of the autophagic machinery, such
as Atg5, Atg7, or Beclin 1 (Becn1), secrete limited amounts of
ATP as they succumb to anthracyclines, and hence are incapable
of vaccinating syngeneic mice against a subsequent challenge
with malignant cells of the same type (57). Such a functional
defect can be corrected by the co-administration of ARL67156,
a broad spectrum inhibitor of extracellular nucleotidases (57).
Further confirming these findings, CT26 engineered to overex-
press CD39 and exposed to anthracyclines are unable to protect
syngeneic mice against a subsequent injection with neoplastic
cells of the same type (57, 125). This defect can be corrected by
the co-administration of ARL67156, along with the restoration of
RCD-associated ATP secretion (57, 125). Taken together, these
results indicate that inhibitors of extracellular nucleotidases may
constitute a convenient manner to boost the immunogenicity
of RCD instances that are normally not associated with ATP
secretion.
Importantly, the pharmacological activation of autophagy does
not suffice for cancer cells to become immunogenic (16, 57).
Nonetheless, combining anticancer agents that per se are unable
to trigger ATP secretion with molecules that upregulate the
autophagic flux, such as inhibitors of mechanistic target of
rapamycin (MTOR) complex I (MTORCI), may efficiently con-
vert non-immunogenic RCD instances into bona fide ICD. This
hypothesis awaits formal experimental confirmation. Indeed,
while other inducers of autophagy such as the glycolytic inhibitor
2-deoxyglucose (126) have been shown to reinstate the immuno-
genicity of etoposide-elicited RCD, such an effect was ascribed
to the restoration of CALR exposure (indeed, etoposide kills
malignant cells while promoting ATP secretion) (100). Finally,
it should be noted that the establishment of an ATP gradient
around dying cells may not constitute a general requirement for
the perception of RCD as immunogenic (127). Moreover, at least
in some settings, autophagy may actually inhibit ICD by limiting
the production of reactive oxygen species in the course of adaptive
stress responses, hence counteracting the establishment of ER
stress and consequentCALR exposure (54, 55). Thus, furtherwork
is required to precisely identify malignancies in which autophagy
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supports ICD. Only in these scenarios, the co-administration of
autophagy inducers may constitute a proper approach to reinstate
the immunogenicity of RCD.
Combinatorial Strategies to Promote Type I
IFN Production
Whereas the role of type I IFN in the regulation of innate and
adaptive immune responses is well known (128, 129), type I IFN
signaling in malignant cells has been identified as a requirement
for (anthracycline-induced) ICD only recently (51). Thus, cancer
cells respond to various anthracyclines by activating a TLR3-
elicited signal transduction cascade resulting in type I IFN release,
autocrine/paracrine type I IFN signaling, and chemokine (C–X–C
motif) ligand 10 (CXCL10) secretion, two phenomena that under-
lie their vaccinating potential. At odds with their wild-type coun-
terparts, Tlr3 /  and Ifnar1 /  murine cancer cells exposed to
anthracyclines fail to vaccinate syngeneic mice against a subse-
quent injection of living cells of the same type (51). It has already
been demonstrated that the inability of Tlr3 /  cells to undergo
ICD can be corrected by the co-administration of recombinant
type I IFNs or recombinant CXCL10. Similarly, Ifnar1 /  cells
succumbing to anthracyclines turn immunogenic in the presence
of recombinant CXCL10 (but not type I IFNs) (51).
Various synthetic TLR3 agonists are available and some of
them, including polyinosinic:polycytidylic acid (polyI:C) and its
clinical grade analog polyI:polyC12U (also known as rintatolimod
and Ampligen™), have been extensively tested as immunostim-
ulants in cancer patients (130, 131). It is therefore tempting to
speculate that the co-administration of TLR3 agonists may restore
the ability of anticancer agents that per se do not promote type
I IFN release to trigger bona fide ICD. This hypothesis awaits
urgent experimental confirmation. For the considerations pre-
sented above, small molecules that trigger TLR3 signaling would
indeed be more convenient as clinical tools to restore type I IFN
signaling than recombinant type I IFN or CXCL10 themselves.
Combinatorial Strategies to Substitute for
HMGB1 Release
HMGB1 release occurs upon (nuclear and) plasma membrane
permeabilization, i.e., it constitutes a post-mortem event (5, 132).
Thus, all antineoplastic agents that efficiently kill malignant cells
(as opposed tomolecules that exert cytostatic effects or induce cell
senescence) (133) promote HMGB1 release, perhaps with differ-
ent kinetics (5, 132). However, the expression levels of HMGB1
vary in different tumor types and evolve along with tumor pro-
gression, implying that somemalignant cellsmay expressHMGB1
to levels that are not compatible with the activation of TLR4 and
RAGE in immune cells upon release (134, 135). Importantly, the
immunogenicity of anthracycline-induced RCD is compromised
in these cells, as well in cells artificially depleted of HMGB1 by
means of specific siRNAs (135). Recent results indicate that this
defect can be efficiently corrected by the exogenous supply of a
synthetic TLR4 agonist, i.e., dendrophilin, at least in experimental
models (135). Since dendrophilin has not yet entered clinical
development (130, 131), it will be interesting to see whether
TLR4 agonists that are already licensed by regulatory agencies
for use in humans, such as the Bacillus Calmette–Guérin (BCG)
(80) and monophosphoryl lipid A (MPL) (136), are also able to
restore the immunogenicity of HMGB1-deficient cells succumb-
ing to ICD.
In this context, it is worth noting that cancer cells exposing
CALR, secreting ATP, producing type I IFNs but releasing limited
amounts of HMGB1 as they respond to a lethal stimulus in a
suboptimalmanner fail to elicit adaptive immune responses (137).
Upon inoculation into immunocompetent mice, these cells actu-
ally form tumors at the vaccination site (as a significant fraction
of them is not dying) and the animals are unable to control a
subsequent challenge with cell of the same type (3). We have
observed this to occur in murine cancer cells treated with digoxin
or digitoxin, two glycosides approved in many countries for the
treatment of cardiac conditions (81). These molecules efficiently
inhibit the human Na+/K+ ATPase, which explains their phar-
macological properties and their ability to kill some neoplastic
cells of human origin, but not its murine counterpart (83). Thus,
cardiac glycosides per se are unable to trigger ICD, at least in
the murine system. However, clinical data indicate that they may
convert non-immunogenic RCD as elicited by a very large panel of
chemotherapeutics into bona fide ICD (83). From another stand-
point, any anticancer agent that efficiently kills malignant cells
could be considered as a means to restore the immunogenicity of
cells responding to cardiac glycosides.We have recently initiated a
clinical trial to prospectively test this hypothesis in head and neck
squamous carcinoma patients.
Concluding Remarks
In spite of old beliefs, cancer cells continuously interact with the
immune system: first, as they are generated by healthy cells upon
malignant transformation; second, as they evolve and acquire
additional neoplastic features; and third, when they are challenged
with therapeutic interventions. During the last decade, such a con-
ceptual revolution, i.e., considering tumors as entities that can be
detected and destroyed by the immune system, has paved the way
toward the development of novel therapeutic agents conceived to
re(instate) anticancer immunity, and some of these interventions
have already been licensed for use in humans by international
regulatory agencies. In addition, it has become clear that many
therapeutics that had been used for decades in the clinic are effi-
cient (for themost part) because they engage the host immune sys-
tem against malignant cells. ICD is one of the several mechanisms
through which cytotoxic chemotherapeutics, targeted anticancer
agents as well as some forms of radiotherapy can elicit tumor-
targeting immune responses. Identifying novel ICD inducers as
well as measures that convert non-immunogenic RCD into bona
fide ICD is of primordial importance. Promising preclinical results
and preliminary clinical findings suggest, indeed, that agents that
promote CALR exposure, ATP secretion, type I IFN production,
HMGB1 release or stimulate the downstream signal transduction
pathway may considerably improve the clinical profile of conven-
tional therapeutic regimens (Figure 1). A systematic investigation
of the ability of currently available anticancer agents to elicit
the abovementioned ICD-associated processes in human cancer
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FIGURE 1 | Strategies to convert non-immunogenic RCD into bona fide
ICD. Upon inoculation into immunocompetent syngeneic hosts, cancer cells
responding to a panel of lethal stimuli trigger an adaptive immune response
against dead cell-associated antigens. Such an immunogenic variant of
regulated cell death (RCD), commonly known as immunogenic cell death (ICD),
relies on the exposure of calreticulin (CALR) on the cell surface, on the secretion
of ATP, on the production of type I interferons (IFNs) and on the release of
high-mobility group box 1 (HMGB1, which accompanies cell death). When any
of these damage-associated molecular patterns cannot be emitted (in the
appropriate spatiotemporal order), dying cancer cells cannot be perceived
anymore as immunogenic by the host immune system. Several strategies have
been conceived to correct these defects, hence converting non-immunogenic
RCD into bona fide ICD. ER, endoplasmic reticulum; IFNAR, interferon (alpha,
beta, and omega) receptor; P2RX7, purinergic receptor P2X, ligand gated ion
channel, 7; P2RY2, purinergic receptor P2Y, G-protein coupled, 2; TLR, toll-like
receptor.
cells of distinct histological origin is urgently awaited. These data
may pave the way to the clinical implementation of combinato-
rial immuno(chemo)regimens that efficiently promote ICD and
hence mediate complete tumor regression in a high proportion of
patients.
Acknowledgments
GK is supported by the Ligue contre le Cancer (équipe labelisée);
Agence National de la Recherche (ANR); Association pour
la recherche sur le cancer (ARC); Cancéropôle Ile-de-France;
Institut National du Cancer (INCa); Fondation Bettencourt-
Schueller; Fondation de France; Fondation pour la Recherche
Médicale (FRM); the European Commission (ArtForce); the
European Research Council (ERC); the LabEx Immuno-
Oncology; the SIRIC Stratified Oncology Cell DNA Repair
and Tumor Immune Elimination (SOCRATE); the SIRIC
Cancer Research and Personalized Medicine (CARPEM);
and the Paris Alliance of Cancer Research Institutes
(PACRI).
Frontiers in Immunology | www.frontiersin.org April 2015 | Volume 6 | Article 1877
Bezu et al. Immunogenic cell death and cancer therapy
References
1. Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, et al.
Activation of dendritic cells by tumor cell death. Oncoimmunology (2012)
1:1218–9. doi:10.4161/onci.20428
2. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P.
Immunogenic cell death andDAMPs in cancer therapy.Nat Rev Cancer (2012)
12:860–75. doi:10.1038/nrc3380
3. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death
in cancer therapy. Annu Rev Immunol (2013) 31:51–72. doi:10.1146/
annurev-immunol-032712-100008
4. Galluzzi L, Kepp O, Krautwald S, Kroemer G, Linkermann A. Molecular
mechanisms of regulated necrosis. SeminCell Dev Biol (2014) 35:24–32. doi:10.
1016/j.semcdb.2014.02.006
5. Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM,
Adam D, et al. Essential versus accessory aspects of cell death: recommenda-
tions of the NCCD 2015. Cell Death Differ (2015) 22:58–73. doi:10.1038/cdd.
2014.137
6. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke
EH, et al. Classification of cell death: recommendations of the Nomenclature
Committee on Cell Death 2009.Cell Death Differ (2009) 16:3–11. doi:10.1038/
cdd.2008.150
7. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman
DC, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic
cell death. EMBO J (2009) 28:578–90. doi:10.1038/emboj.2009.1
8. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny
MV, et al. Molecular definitions of cell death subroutines: recommendations
of the Nomenclature Committee on Cell Death 2012. Cell Death Differ (2012)
19:107–20. doi:10.1038/cdd.2011.96
9. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, et al.
Consensus guidelines for the detection of immunogenic cell death. Oncoim-
munology (2014) 3:e955691. doi:10.4161/21624011.2014.955691
10. Sukkurwala AQ, Adjemian S, Senovilla L, Michaud M, Spaggiari S, Vacchelli
E, et al. Screening of novel immunogenic cell death inducers within the NCI
mechanistic diversity set.Oncoimmunology (2014) 3:e28473. doi:10.4161/onci.
28473
11. Dudek AM, Garg AD, Krysko DV, De Ruysscher D, Agostinis P. Inducers of
immunogenic cancer cell death.CytokineGrowth Factor Rev (2013) 24:319–33.
doi:10.1016/j.cytogfr.2013.01.005
12. Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L,
et al. Trial watch: chemotherapy with immunogenic cell death inducers.
Oncoimmunology (2013) 2:e23510. doi:10.4161/onci.23510
13. Kepp O, Senovilla L, Kroemer G. Immunogenic cell death inducers as anti-
cancer agents. Oncotarget (2014) 5:5190–1.
14. Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Cremer
I, et al. Trial watch: chemotherapy with immunogenic cell death inducers.
Oncoimmunology (2014) 3:e27878. doi:10.4161/onci.27878
15. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N,
et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell
death. J Exp Med (2005) 202:1691–701. doi:10.1084/jem.20050915
16. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al.
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat
Med (2007) 13:54–61. doi:10.1038/nm1523
17. Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J,
et al. Human tumor cells killed by anthracyclines induce a tumor-specific
immune response. Cancer Res (2011) 71:4821–33. doi:10.1158/0008-5472.
CAN-11-0950
18. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al.
Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene
(2010) 29:482–91. doi:10.1038/onc.2009.356
19. Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, et al.
Restoration of the immunogenicity of cisplatin-induced cancer cell death by
endoplasmic reticulum stress. Oncogene (2011) 30:1147–58. doi:10.1038/onc.
2010.500
20. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F,
et al. Cyclophosphamide synergizes with type I interferons through
systemic dendritic cell reactivation and induction of immunogenic
tumor apoptosis. Cancer Res (2011) 71:768–78. doi:10.1158/0008-5472.
CAN-10-2788
21. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomod-
ulatory effects of cyclophosphamide and implementations for vaccine design.
Semin Immunopathol (2011) 33:369–83. doi:10.1007/s00281-011-0245-0
22. Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U,
et al. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in
breast cancer patients during neoadjuvant chemotherapy. Tumour Biol (2013)
34:81–90. doi:10.1007/s13277-012-0513-1
23. Ziccheddu G, Proietti E, Moschella F. The Janus face of cyclophosphamide:
a sterile inflammatory response that potentiates cancer immunotherapy.
Oncoimmunology (2013) 2:e25789. doi:10.4161/onci.25789
24. Demaria S, Santori FR, Ng B, Liebes L, Formenti SC, Vukmanovic S. Select
forms of tumor cell apoptosis induce dendritic cell maturation. J Leukoc Biol
(2005) 77:361–8. doi:10.1189/jlb.0804478
25. Spisek R, Charalambous A,Mazumder A, Vesole DH, Jagannath S, Dhodapkar
MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immu-
nity to human myeloma via exposure of cell surface heat shock protein 90
on dying tumor cells: therapeutic implications. Blood (2007) 109:4839–45.
doi:10.1182/blood-2006-10-054221
26. Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, et al. Primary
effusion lymphoma cell death induced by bortezomib and AG 490 activates
dendritic cells through CD91. PLoS One (2012) 7:e31732. doi:10.1371/journal.
pone.0031732
27. KorbelikM, Sun J, Cecic I. Photodynamic therapy-induced cell surface expres-
sion and release of heat shock proteins: relevance for tumor response. Cancer
Res (2005) 65:1018–26.
28. Korbelik M, ZhangW, Merchant S. Involvement of damage-associated molec-
ular patterns in tumor response to photodynamic therapy: surface expres-
sion of calreticulin and high-mobility group box-1 release. Cancer Immunol
Immunother (2011) 60:1431–7. doi:10.1007/s00262-011-1047-x
29. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. Hypericin-based photo-
dynamic therapy induces surface exposure of damage-associated molecular
patterns like HSP70 and calreticulin. Cancer Immunol Immunother (2012)
61:215–21. doi:10.1007/s00262-011-1184-2
30. Galluzzi L, Kepp O, Kroemer G. Immunogenic cell death in radiation therapy.
Oncoimmunology (2013) 2:e26536. doi:10.4161/onci.26536
31. Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautes-Fridman C, Galon J,
et al. Trial watch: anticancer radioimmunotherapy. Oncoimmunology (2013)
2:e25595. doi:10.4161/onci.25595
32. Bloy N, Pol J, Manic G, Vitale I, Eggermont A, Galon J, et al. Trial watch:
radioimmunotherapy for oncological indications. Oncoimmunology (2014)
3:e954929. doi:10.4161/21624011.2014.954929
33. Garg AD, Agostinis P. ER stress, autophagy and immunogenic cell death in
photodynamic therapy-induced anti-cancer immune responses. Photochem
Photobiol Sci (2014) 13:474–87. doi:10.1039/c3pp50333j
34. Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin
Radiat Oncol (2015) 25:11–7. doi:10.1016/j.semradonc.2014.07.005
35. Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, et al.
Measles virus causes immunogenic cell death in humanmelanoma.Gene Ther
(2013) 20:7–15. doi:10.1038/gt.2011.205
36. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G,
et al. Trial watch: oncolytic viruses for cancer therapy.Oncoimmunology (2013)
2:e24612. doi:10.4161/onci.25238
37. Workenhe ST, Mossman KL. Rewiring cancer cell death to enhance oncolytic
viro-immunotherapy. Oncoimmunology (2013) 2:e27138. doi:10.4161/onci.
27138
38. Workenhe ST, Pol JG, Lichty BD, Cummings DT, Mossman KL. Combining
oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone
breaks cancer immune tolerance and improves therapeutic efficacy. Cancer
Immunol Res (2013) 1:309–19. doi:10.1158/2326-6066.CIR-13-0059-T
39. Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, et al. Trial
watch: oncolytic viruses for cancer therapy.Oncoimmunology (2014) 3:e28694.
doi:10.4161/onci.28185
40. Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L,
et al. Improved cellular pharmacokinetics andpharmacodynamics underlie the
wide anticancer activity of sagopilone. Cancer Res (2008) 68:5301–8. doi:10.
1158/0008-5472.CAN-08-0237
41. Pellicciotta I, Yang CP, Goldberg GL, Shahabi S. Epothilone B enhances Class I
HLA andHLA-A2 surfacemolecule expression in ovarian cancer cells.Gynecol
Oncol (2011) 122:625–31. doi:10.1016/j.ygyno.2011.05.007
Frontiers in Immunology | www.frontiersin.org April 2015 | Volume 6 | Article 1878
Bezu et al. Immunogenic cell death and cancer therapy
42. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, et al. An
immunosurveillance mechanism controls cancer cell ploidy. Science (2012)
337:1678–84. doi:10.1126/science.1224922
43. Fucikova J, Moserova I, Truxova I, Hermanova I, Vancurova I, Partlova S, et al.
High hydrostatic pressure induces immunogenic cell death in human tumor
cells. Int J Cancer (2014) 135:1165–77. doi:10.1002/ijc.28766
44. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation
and immunity. Cell (2010) 140:798–804. doi:10.1016/j.cell.2010.02.015
45. Galluzzi L, Bravo-San Pedro JM, Kroemer G. Organelle-specific initiation of
cell death. Nat Cell Biol (2014) 16:728–36. doi:10.1038/ncb3005
46. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P.
Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging
amalgamation. Biochim Biophys Acta (2010) 1805:53–71. doi:10.1016/j.bbcan.
2009.08.003
47. Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger
signalling. Nat Rev Mol Cell Biol (2012) 13:780–8. doi:10.1038/nrm3479
48. Garg AD, Dudek AM, Agostinis P. Cancer immunogenicity, danger signals,
and DAMPs: what, when, and how? Biofactors (2013) 39:355–67. doi:10.1002/
biof.1125
49. Krysko O, Love Aaes T, Bachert C, Vandenabeele P, Krysko DV. Many faces
of DAMPs in cancer therapy. Cell Death Dis (2013) 4:e631. doi:10.1038/cddis.
2013.156
50. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al.
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-
dependent adaptive immunity against tumors. Nat Med (2009) 15:1170–8.
doi:10.1038/nm.2028
51. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. Cancer
cell-autonomous contribution of type I interferon signaling to the efficacy of
chemotherapy. Nat Med (2014) 20:1301–9. doi:10.1038/nm.3708
52. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-
like receptor 4-dependent contribution of the immune system to anticancer
chemotherapy and radiotherapy. Nat Med (2007) 13:1050–9. doi:10.1038/
nm1622
53. Galluzzi L, Kepp O, Kroemer G. Enlightening the impact of immunogenic
cell death in photodynamic cancer therapy. EMBO J (2012) 31:1055–7. doi:10.
1038/emboj.2012.2
54. Garg AD, Dudek AM, Agostinis P. Autophagy-dependent suppression of
cancer immunogenicity and effector mechanisms of innate and adaptive
immunity. Oncoimmunology (2013) 2:e26260. doi:10.4161/onci.26260
55. Garg AD, Dudek AM, Ferreira GB, Verfaillie T, Vandenabeele P, Krysko DV,
et al. ROS-induced autophagy in cancer cells assists in evasion from determi-
nants of immunogenic cell death. Autophagy (2013) 9:1292–307. doi:10.4161/
auto.25399
56. Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T, et al.
Crosstalk between ER stress and immunogenic cell death. Cytokine Growth
Factor Rev (2013) 24:311–8. doi:10.1016/j.cytogfr.2013.05.001
57. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al.
Autophagy-dependent anticancer immune responses induced by chemothera-
peutic agents inmice. Science (2011) 334:1573–7. doi:10.1126/science.1208347
58. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T,
et al. A novel pathway combining calreticulin exposure and ATP secretion
in immunogenic cancer cell death. EMBO J (2012) 31:1062–79. doi:10.1038/
emboj.2011.497
59. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al.
Nucleotides released by apoptotic cells act as a find-me signal to promote
phagocytic clearance. Nature (2009) 461:282–6. doi:10.1038/nature08296
60. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anti-
cancer chemotherapy-induced intratumoral recruitment and differentiation of
antigen-presenting cells. Immunity (2013) 38:729–41. doi:10.1016/j.immuni.
2013.03.003
61. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by
necrotic cells triggers inflammation. Nature (2002) 418:191–5. doi:10.1038/
nature00858
62. Ma Y, Adjemian S, Yang H, Catani JP, Hannani D, Martins I, et al. ATP-
dependent recruitment, survival and differentiation of dendritic cell precur-
sors in the tumor bed after anticancer chemotherapy.Oncoimmunology (2013)
2:e24568. doi:10.4161/onci.24568
63. Michaud M, Xie X, Bravo-San Pedro JM, Zitvogel L, White E, Kroemer G. An
autophagy-dependent anticancer immune response determines the efficacy of
melanoma chemotherapy. Oncoimmunology (2014) 3:e944047. doi:10.4161/
21624011.2014.944047
64. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G.
Prognostic and predictive impact of intra- and peritumoral immune infiltrates.
Cancer Res (2011) 71:5601–5. doi:10.1158/0008-5472.CAN-11-1316
65. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contex-
ture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012)
12:298–306. doi:10.1038/nrc3245
66. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH,
et al. Trial watch: prognostic and predictive value of the immune infiltrate in
cancer. Oncoimmunology (2012) 1:1323–43. doi:10.4161/onci.22009
67. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC,
et al. Spatiotemporal dynamics of intratumoral immune cells reveal the
immune landscape in human cancer. Immunity (2013) 39:782–95. doi:10.
1016/j.immuni.2013.10.003
68. Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM,
et al. Prognostic and predictive values of the immunoscore in patients with
rectal cancer. Clin Cancer Res (2014) 20:1891–9. doi:10.1158/1078-0432.
CCR-13-2830
69. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al.
PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Nature (2014) 515:568–71. doi:10.1038/nature13954
70. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostim-
ulation by anticancer drugs. Nat Rev Drug Discov (2012) 11:215–33. doi:10.
1038/nrd3626
71. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of con-
ventional and targeted anticancer therapies: reinstating immunosurveillance.
Immunity (2013) 39:74–88. doi:10.1016/j.immuni.2013.06.014
72. Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G,
et al. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology
(2013) 2:e22789. doi:10.4161/onci.25238
73. Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, et al.
Trial watch: immunostimulatory monoclonal antibodies in cancer therapy.
Oncoimmunology (2014) 3:e27297. doi:10.4161/onci.27297
74. Robert C, Thomas L, Bondarenko I, O’day S, Weber J, Garbe C, et al. Ipil-
imumab plus dacarbazine for previously untreated metastatic melanoma. N
Engl J Med (2011) 364:2517–26. doi:10.1056/NEJMoa1104621
75. Eggermont AM, Robert C. Melanoma: smart therapeutic strategies in
immuno-oncology. Nat Rev Clin Oncol (2014) 11:181–2. doi:10.1038/
nrclinonc.2014.36
76. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al.
Anti-programmed-death-receptor-1 treatment with pembrolizumab
in ipilimumab-refractory advanced melanoma: a randomised dose-
comparison cohort of a phase 1 trial. Lancet (2014) 384:1109–17.
doi:10.1016/S0140-6736(14)60958-2
77. Robert C, Long GV, Brady B, Dutriaux C, MaioM,Mortier L, et al. Nivolumab
in previously untreated melanoma without BRAF mutation. N Engl J Med
(2015) 372:320–30. doi:10.1056/NEJMoa1412082
78. Galluzzi L, Kroemer G, Eggermont A. Novel immune checkpoint blocker
approved for the treatment of advanced melanoma. Oncoimmunology (2014)
3:e967147. doi:10.1016/j.clindermatol.2012.08.006
79. Vacchelli E, Prada N, Kepp O, Galluzzi L. Current trends of anticancer
immunochemotherapy. Oncoimmunology (2013) 2:e25396. doi:10.4161/onci.
25396
80. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, BuqueA, Senovilla L, Baracco EE,
et al. Classification of current anticancer immunotherapies.Oncotarget (2014)
5:12472–508.
81. Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, et al. Cardiac
glycosides exert anticancer effects by inducing immunogenic cell death. Sci
Transl Med (2012) 4:143ra199. doi:10.1126/scitranslmed.3003807
82. Kono K, Mimura K. Immunogenic tumor cell death induced by chemoradio-
therapy in a clinical setting. Oncoimmunology (2013) 2:e22197. doi:10.4161/
onci.22197
83. Menger L, Vacchelli E, Kepp O, Eggermont A, Tartour E, Zitvogel L, et al.
Trial watch: cardiac glycosides and cancer therapy. Oncoimmunology (2013)
2:e23082. doi:10.4161/onci.23082
84. Palombo F, Focaccetti C, Barnaba V. Therapeutic implications of immuno-
genic cell death in human cancer. Front Immunol (2014) 4:503. doi:10.3389/
fimmu.2013.00503
Frontiers in Immunology | www.frontiersin.org April 2015 | Volume 6 | Article 1879
Bezu et al. Immunogenic cell death and cancer therapy
85. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular
mechanisms of cisplatin resistance.Oncogene (2012) 31:1869–83. doi:10.1038/
onc.2011.384
86. Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M,
Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced
immunogenic cell death.Oncoimmunology (2014) 3:e28518. doi:10.4161/onci.
28518
87. Yamamura Y, Tsuchikawa T, Miyauchi K, Takeuchi S, Wada M, Kuwatani
T, et al. The key role of calreticulin in immunomodulation induced by
chemotherapeutic agents. Int J Clin Oncol (2015) 20:386–94. doi:10.1007/
s10147-014-0719-x
88. Bugaut H, Bruchard M, Berger H, Derangere V, Odoul L, Euvrard R, et al.
Bleomycin exerts ambivalent antitumor immune effect by triggering both
immunogenic cell death and proliferation of regulatory T cells. PLoS One
(2013) 8:e65181. doi:10.1371/journal.pone.0065181
89. Chang CL, Hsu YT, Wu CC, Yang YC, Wang C, Wu TC, et al. Immune
mechanism of the antitumor effects generated by bortezomib. J Immunol
(2012) 189:3209–20. doi:10.4049/jimmunol.1103826
90. Aranda F, Bloy N, Galluzzi L, Kroemer G, Senovilla L. Vitamin B6 improves
the immunogenicity of cisplatin-induced cell death. Oncoimmunology (2014)
3:e955685. doi:10.4161/21624011.2014.955685
91. Aranda F, Bloy N, Pesquet J, Petit B, Chaba K, Sauvat A, et al. Immune-
dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell
lung cancer. Oncogene (2014). doi:10.1038/onc.2014.234
92. Cirone M, Garufi A, Di Renzo L, Granato M, Faggioni A, D’orazi G. Zinc
supplementation is required for the cytotoxic and immunogenic effects of
chemotherapy in chemoresistant p53-functionally deficient cells. Oncoim-
munology (2013) 2:e26198. doi:10.4161/onci.26198
93. Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L,
et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle (2009)
8:3723–8. doi:10.4161/cc.8.22.10026
94. Mihailidou C, Chatzistamou I, Papavassiliou A, Kiaris H. Improvement of
chemotherapeutic drug efficacy by endoplasmic reticulum stress. Endocr Relat
Cancer (2015) 22(2):229–38. doi:10.1530/ERC-15-0019
95. Chen X, Yang Y, Zhou Q, Weiss JM, Howard OZ, McPherson JM, et al.
Effective chemoimmunotherapy with anti-TGFbeta antibody and cyclophos-
phamide in a mouse model of breast cancer. PLoS One (2014) 9:e85398.
doi:10.1371/journal.pone.0085398
96. Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, et al.
Chemotherapy-induced immunogenic modulation of tumor cells enhances
killing by cytotoxic T lymphocytes and is distinct from immunogenic cell
death. Int J Cancer (2013) 133:624–36. doi:10.1002/ijc.28070
97. Wang W, Qin S, Zhao L. Docetaxel enhances CD3+ CD56+ cytokine-induced
killer cells-mediated killing through inducing tumor cells phenotype modu-
lation. Biomed Pharmacother (2015) 69:18–23. doi:10.1016/j.biopha.2014.10.
026
98. Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, et al.
Contribution of IL-17-producing gamma delta T cells to the efficacy of
anticancer chemotherapy. J Exp Med (2011) 208:491–503. doi:10.1084/jem.
20100269
99. Zappasodi R, Pupa SM,GhediniGC, Bongarzone I,MagniM,CabrasAD, et al.
Improved clinical outcome in indolent B-cell lymphoma patients vaccinated
with autologous tumor cells experiencing immunogenic death. Cancer Res
(2010) 70:9062–72. doi:10.1158/0008-5472.CAN-10-1825
100. Beneteau M, Zunino B, Jacquin MA, Meynet O, Chiche J, Pradelli LA, et al.
Combination of glycolysis inhibition with chemotherapy results in an anti-
tumor immune response. Proc Natl Acad Sci U S A (2012) 109:20071–6.
doi:10.1073/pnas.1206360109
101. Boyd-Tressler A, Penuela S, Laird DW, Dubyak GR. Chemotherapeu-
tic drugs induce ATP release via caspase-gated pannexin-1 channels
and a caspase/pannexin-1-independent mechanism. J Biol Chem (2014)
289:27246–63. doi:10.1074/jbc.M114.590240
102. Kepp O, Galluzzi L, Giordanetto F, Tesniere A, Vitale I, Martins I, et al.
Disruption of the PP1/GADD34 complex induces calreticulin exposure. Cell
Cycle (2009) 8:3971–7. doi:10.4161/cc.8.23.10191
103. Zhao T, Ren H, Jia L, Chen J, Xin W, Yan F, et al. Inhibition of HIF-
1alpha by PX-478 enhances the anti-tumor effect of gemcitabine by inducing
immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget
(2015) 6:2250–62.
104. Wemeau M, Kepp O, Tesniere A, Panaretakis T, Flament C, De Botton S,
et al. Calreticulin exposure on malignant blasts predicts a cellular anticancer
immune response in patients with acute myeloid leukemia. Cell Death Dis
(2010) 1:e104. doi:10.1038/cddis.2010.82
105. Frey B, Stache C, Rubner Y, Werthmoller N, Schulz K, Sieber R, et al. Com-
bined treatment of human colorectal tumor cell lines with chemotherapeutic
agents and ionizing irradiation can in vitro induce tumor cell death forms
with immunogenic potential. J Immunotoxicol (2012) 9:301–13. doi:10.3109/
1547691X.2012.693547
106. Dudek-Peric AM, Ferreira GB, Muchowicz A, Wouters J, Prada N, Martin S,
et al. Antitumor immunity triggered bymelphalan is potentiated bymelanoma
cell surface-associated calreticulin.Cancer Res (2015). doi:10.1158/0008-5472.
CAN-14-2089
107. Lu X, Ding ZC, Cao Y, Liu C, Habtetsion T, Yu M, et al. Alkylating agent
melphalan augments the efficacy of adoptive immunotherapy using tumor-
specific CD4+ T cells. J Immunol (2015) 194:2011–21. doi:10.4049/jimmunol.
1401894
108. Zhou P, Teruya-Feldstein J, Lu P, Fleisher M, Olshen A, Comenzo RL. Calreti-
culin expression in the clonal plasma cells of patients with systemic light-chain
(AL-) amyloidosis is associated with response to high-dose melphalan. Blood
(2008) 111:549–57. doi:10.1182/blood-2007-11-125526
109. Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag
M, et al. The co-translocation of ERp57 and calreticulin determines the
immunogenicity of cell death. Cell Death Differ (2008) 15:1499–509. doi:10.
1038/cdd.2008.67
110. Gou HF, Huang J, Shi HS, Chen XC, Wang YS. Chemo-immunotherapy with
oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice. PLoS
One (2014) 9:e85789. doi:10.1371/journal.pone.0085789
111. Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi
P, et al. Oncolytic adenovirus with temozolomide induces autophagy and
antitumor immune responses in cancer patients.Mol Ther (2013) 21:1212–23.
doi:10.1038/mt.2013.51
112. Rubner Y, Muth C, Strnad A, Derer A, Sieber R, Buslei R, et al. Fractionated
radiotherapy is the main stimulus for the induction of cell death and of Hsp70
release of p53mutated glioblastoma cell lines.Radiat Oncol (2014) 9:89. doi:10.
1186/1748-717X-9-89
113. Martin S, Dudek-Peric AM, Maes H, Garg AD, Gabrysiak M, Demirsoy S,
et al. Concurrent MEK and autophagy inhibition is required to restore cell
death associated danger-signalling in vemurafenib-resistant melanoma cells.
Biochem Pharmacol (2015) 93:290–304. doi:10.1016/j.bcp.2014.12.003
114. Hetz C. The unfolded protein response: controlling cell fate decisions under
ER stress and beyond. Nat Rev Mol Cell Biol (2012) 13:89–102. doi:10.1038/
nrm3270
115. Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, et al.
Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep (2012)
2:257–69. doi:10.1016/j.celrep.2012.06.017
116. Steiner P, Kulangara K, Sarria JC, Glauser L, Regazzi R, Hirling H. Reticu-
lon 1-C/neuroendocrine-specific protein-C interacts with SNARE proteins. J
Neurochem (2004) 89:569–80. doi:10.1111/j.1471-4159.2004.02345.x
117. Michaud M, Sukkurwala AQ, Di Sano F, Zitvogel L, Kepp O, Kroemer G.
Synthetic induction of immunogenic cell death by genetic stimulation of
endoplasmic reticulum stress.Oncoimmunology (2014) 3:e28276. doi:10.4161/
onci.28276
118. Dubois SG, Grier HE. Chemotherapy: the role of ifosfamide and etoposide in
Ewing sarcoma. Nat Rev Clin Oncol (2009) 6:251–3. doi:10.1038/nrclinonc.
2009.25
119. Johnson FM, Glisson BS. Chemotherapy: irinotecan or etoposide as front-line
therapy for SCLC? Nat Rev Clin Oncol (2009) 6:562–3. doi:10.1038/nrclinonc.
2009.141
120. Kepp O, Semeraro M, Pedro JM, Bloy N, Buque A, Huang X, et al. eIF2alpha
phosphorylation as a biomarker of immunogenic cell death. Semin Cancer Biol
(2015). doi:10.1016/j.semcancer.2015.02.004
121. Ma Y, Galluzzi L, Zitvogel L, Kroemer G. Autophagy and cellular immune
responses. Immunity (2013) 39:211–27. doi:10.1016/j.immuni.2013.07.017
122. Green DR, Galluzzi L, Kroemer G. Mitochondria and the autophagy-
inflammation-cell death axis in organismal aging. Science (2011) 333:1109–12.
doi:10.1126/science.1201940
123. Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK,
Baehrecke EH, Cecconi F, et al. Autophagy in malignant transformation
Frontiers in Immunology | www.frontiersin.org April 2015 | Volume 6 | Article 18710
Bezu et al. Immunogenic cell death and cancer therapy
and cancer progression. EMBO J (2015) 34(7):856–80. doi:10.15252/embj.
201490784
124. Martins I,Wang Y,MichaudM,Ma Y, Sukkurwala AQ, Shen S, et al. Molecular
mechanisms of ATP secretion during immunogenic cell death. Cell Death
Differ (2014) 21:79–91. doi:10.1038/cdd.2013.75
125. Michaud M, Sukkurwala AQ, Martins I, Shen S, Zitvogel L, Kroemer
G. Subversion of the chemotherapy-induced anticancer immune response
by the ecto-ATPase CD39. Oncoimmunology (2012) 1:393–5. doi:10.4161/
onci.19070
126. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets
for cancer therapy. Nat Rev Drug Discov (2013) 12:829–46. doi:10.1038/
nrd4191
127. Koks CA, Garg AD, Ehrhardt M, Riva M, Vandenberk L, Boon L, et al.
Newcastle disease virotherapy induces long-term survival and tumor-specific
immunememory in orthotopic glioma through the induction of immunogenic
cell death. Int J Cancer (2015) 136:E313–25. doi:10.1002/ijc.29202
128. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev
Immunol (2014) 14:36–49. doi:10.1038/nri3581
129. McNab F, Mayer-Barber K, Sher A, Wack A, O’garra A. Type I interferons in
infectious disease. Nat Rev Immunol (2015) 15:87–103. doi:10.1038/nri3787
130. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G,
et al. Trial watch: toll-like receptor agonists for cancer therapy. Oncoimmunol-
ogy (2013) 2:e25238. doi:10.4161/onci.25238
131. Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautes-Fridman
C, et al. Trial watch: toll-like receptor agonists in oncological indications.
Oncoimmunology (2014) 3:e29179. doi:10.4161/onci.29179
132. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear
weapon in the immune arsenal. Nat Rev Immunol (2005) 5:331–42. doi:10.
1038/nri1594
133. Lopez-Otin C, BlascoMA, Partridge L, SerranoM, Kroemer G. The hallmarks
of aging. Cell (2013) 153:1194–217. doi:10.1016/j.cell.2013.05.039
134. Pang X, Zhang Y, Wei H, Zhang J, Luo Q, Huang C, et al. Expression and
effects of high-mobility group box 1 in cervical cancer. Int J Mol Sci (2014)
15:8699–712. doi:10.3390/ijms15058699
135. Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A,
et al. Defective immunogenic cell death of HMGB1-deficient tumors: com-
pensatory therapy with TLR4 agonists. Cell Death Differ (2014) 21:69–78.
doi:10.1038/cdd.2013.72
136. Srivastava AK, Dinc G, Sharma RK, Yolcu ES, Zhao H, Shirwan H. SA-4-1BBL
and monophosphoryl lipid A constitute an efficacious combination adjuvant
for cancer vaccines. Cancer Res (2014) 74:6441–51. doi:10.1158/0008-5472.
CAN-14-1768-A
137. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M,
et al. Molecular determinants of immunogenic cell death elicited by anti-
cancer chemotherapy. Cancer Metastasis Rev (2011) 30:61–9. doi:10.1007/
s10555-011-9273-4
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest. The Guest Associate Editor, Patrizia
Agostinis, declares that despite having co-authored a few manuscripts with the
authors LorenzoGalluzzi, Oliver Kepp andGuido Kroemer in the past 2 years, there
has been no conflict of interest during the review and handling of this manuscript.
Copyright © 2015 Bezu, Gomes-da-Silva, Dewitte, Breckpot, Fucikova, Spisek, Gal-
luzzi, Kepp and Kroemer. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordancewith
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org April 2015 | Volume 6 | Article 18711
